Aluminium chloride 35% / Isopropyl alcohol 32.5% solution
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Aluminium chloride + Isopropyl alcohol
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · 1978–2026
Showing the 50 most relevant studies, sorted by most relevant.
Isufi D, Jensen MB, Kursawe Larsen C, et al.
2025
- Dermatitis, Allergic Contact
- Allergens
- Patch Tests
Contact allergy (CA) is a frequent condition in children; however, newer estimates of the prevalence of CA in children are lacking. Herein, we aim to provide an estimate of the prevalence of CA in children from 2010 to 2024. Two authors independently searched PubMed, Embase and Web of Science for studies reporting the prevalence of positive patch tests (PPTs) to allergens in populations including ≥ 100 children (< 18 years). Proportion meta-analyses were conducted to calculate the pooled prevalence estimates of CA in children. Seventeen studies comprising 11 593 children undergoing patch testing with 4176 (36%) PPTs were eligible for inclusion. The allergen with the highest prevalence was nickel (11.9% [95% confidence interval [CI], 8.6%-15.71%]), followed by cobalt (6.6% [95% CI, 4.2%-9.5%]), cocamidopropyl betaine (5.5% [95% CI, 3.1-8.7]), bacitracin (5.2% [95% CI, 1.2%-10.0%]), fragrance mix I (4.8% [95% CI, 2.9%-7.1%]) and methylisothiazolinone (4.3% [95% CI, 2.2%-7.2%]). Children with atopic dermatitis had higher rates of PPTs for cocamidopropyl betaine, propylene glycol, lanolin alcohol and carba mix. Across geographical areas, higher prevalences of several allergens were found in the United States compared to Europe, for example, for methylisothiazolinone. This meta-analysis confirmed that CA is frequent in children across geographical areas; however, differences in the frequency of top allergens depend on regulatory interventions, indicating their value.
Abstract licence: CC BY
Byung-Wook Park, Hyoung-Woo Kwon, Yonghui Lee, et al.
Nature Energy, 2021
Joanna Korzekwa
REVIEWS ON ADVANCED MATERIALS SCIENCE, 2023
Pitriani P, Mulyani AT, Wardhana YW, et al.
2026
- Dietary Supplements
- Polymers
- Pharmaceutical Preparations
Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to chemical degradation, physical instability, and compromised therapeutic efficacy. This narrative literature review, evaluated the comparative effectiveness of various polymeric systems and coating technologies as moisture barriers across diverse dosage forms, including tablets, powders, granules, and particulates. We analyzed a spectrum of barrier materials, including cellulose derivatives, polyvinylpyrrolidone, polyvinyl alcohol (PVA), methacrylates, and shellac, contrasting conventional solvent based techniques (fluid bed, spray drying, freeze drying coating) with advanced methodologies (hot melt coating, electrostatic dry coating, and Atomic Layer Deposition/ALD). Conventional coating systems utilizing HPMC and PVA were found to maintain moisture uptake below 1.5% during long-term storage (40°C/75% RH). However, more advanced strategies demonstrated superior protective capabilities, for instance, hotmelt coating employing lipid-based excipients (Precirol ATO 5) reduced moisture absorption by up to 85% at 75% RH. Furthermore, electrostatic dry coating showed a significant reduction in weight gain, decreasing from 6.5% to 3.3% compared to uncoated cores over a 48-hour period. Notably, ALD provided the most robust protection, preserving the amorphous stability of sensitive particles for up to two years under extreme conditions. This review highlights that film coatings not only mitigate moisture induced degradation but also enhance shelf life and improve the mechanical properties of dosage forms. These results underscore the versatility of coating technologies, enabling formulators to tailor strategies for highly moisture sensitive compounds.
Abstract licence: CC BY-NC
D. Herranz, Ricardo Escudero Cid, M. Montiel, et al.
Renewable Energy, 2018
K. Scholes, K. Crow, J. Ellis, et al.
British Medical Journal, 1978
Meiling Han, Zheng Yao, Qing Ye, et al.
International journal of biological macromolecules, 2024
Kulsum Bano, Jyoti Sharma, Archana Jain, et al.
RSC Advances, 2023
S. Tucker, J. Balko, Dustin C Smith, et al.
PeerJ, 2023
While cockroaches are commonly exhibited in zoos and museums, studied in research laboratories, and even kept as pets, scientifically based guidelines for their euthanasia are lacking. This study assessed euthanasia techniques in four species of cockroaches (Dubia (Blaptica dubia), red runner (Shelfordella lateralis), Madagascar hissing (Gromphadorhina portentosa), and giant cave (Blaberus giganteus)). In an initial pilot study, two hundred fifty adult Dubia cockroaches were exposed in groups of ten to a cotton ball soaked with 2 mL of isoflurane in a 1 L air-tight chamber. Thirty minutes beyond loss of any individual movement, groups were exposed to one of the following secondary treatments: freezing at −18 °C or −80 °C from 0.25 to 24 hours; immersion in 10% neutral buffered formalin, 70% isopropyl alcohol, or reverse osmosis water for 0.25 or 0.5 hours; or intracoelomic injection of potassium chloride (456 mEq/kg) or pentobarbital-based euthanasia solution (3.9 g/kg). A control group remained in the air-tight isoflurane chamber for 24 hours. Following all treatments, cockroaches were monitored for an additional 24 hours for spontaneous movement. Irreversible loss of movement was considered synonymous with irreversible loss of consciousness (death). Across all species, isoflurane anesthesia followed by either 70% isopropyl alcohol immersion for 0.25 or 0.5 hours or isoflurane exposure for 24 hours resulted in euthanasia in 100% of cockroaches. This study is the first evaluation of American Veterinary Medical Association-recommended euthanasia protocols in cockroaches.
Abstract licence: CC BY
Murilo Oliveira Alves Ferreira, João Pedro Lopes do Nascimento, Natália Bueno Leite, et al.
Materials Research, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.